300573.SHE Shenyang Xingqi Pharmaceutical Co Ltd
- Market cap
- CNY 12.2B
- P/E
- 15.4x
- P/B
- 5.34x
- ROE
- 42.1%
- Dividend yield
- 2.88%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300573.SHE undervalued?
Graham number300573.SHE trades 90.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenyang Xingqi Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shenyang Xingqi Pharmaceutical Co Ltd yet.
Shenyang Xingqi Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ophthalmic drugs in the People's Republic of China. The company offers myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory and anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs, intraocular rinsing fluids, pupil dilatant and cilia…
Full company profileShenyang Xingqi Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenyang Xingqi Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 339M | 360M | 431M | 542M | 689M | 1.03B | 1.25B | 1.47B | 1.94B | 2.47B | 2.98B |
| Gross Profit | 254M | 265M | 310M | 395M | 501M | 799M | 980M | 1.13B | 1.52B | 2.01B | 2.47B |
| Operating Income | 58.1M | 46.1M | 11.5M | 37.7M | 106M | 248M | 250M | 277M | 425M | 844M | 1.11B |
| EBITDA | 95.8M | 81.7M | 46.7M | 78.0M | 158M | 298M | 297M | 340M | 500M | 917M | 1.08B |
| Net Income | 54.3M | 39.4M | 13.7M | 35.9M | 88.0M | 195M | 212M | 240M | 338M | 696M | 940M |
| EPS | 0.90 | 0.49 | 0.17 | 0.32 | 1.08 | 2.27 | 1.71 | 1.93 | 1.93 | 1.95 | 2.65 |
| Balance Sheet | |||||||||||
| Total Assets | 721M | 676M | 708M | 852M | 1.00B | 1.69B | 1.78B | 2.02B | 2.13B | 2.54B | 2.99B |
| Total Liabilities | 200M | 123M | 154M | 277M | 309M | 342M | 231M | 334M | 534M | 561M | 763M |
| Shareholders' Equity | 521M | 550M | 546M | 569M | 682M | 1.34B | 1.55B | 1.69B | 1.59B | 1.98B | 2.23B |
| Cash & Short-term Investments | 90.6M | 22.3M | 28.4M | 50.0M | 37.2M | 686M | 515M | 480M | 370M | 394M | 538M |
| Total Debt | 80.0M | 50.0M | 50.0M | 90.0M | 110M | 107M | 6.69M | 72.3M | 209M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 28.1M | 32.7M | 44.0M | 74.1M | 122M | 307M | 286M | 318M | 417M | 753M | - |
| Capital Expenditure | 3.62M | 29.3M | 45.3M | 70.0M | 108M | 95.1M | 299M | 262M | 199M | 271M | 185M |
| Free Cash Flow | 24.5M | 3.41M | -1.28M | 4.11M | 14.0M | 212M | -13.0M | 55.6M | 218M | 483M | 765M |
| Ratios | |||||||||||
| ROE | 10.4% | 7.2% | 2.5% | 6.3% | 12.9% | 14.5% | 13.6% | 14.2% | 21.2% | 35.2% | 42.1% |
| ROA | 7.5% | 5.8% | 1.9% | 4.2% | 8.8% | 11.5% | 11.9% | 11.9% | 15.9% | 27.4% | 31.4% |
| Net Profit Margin | 16.0% | 11.0% | 3.2% | 6.6% | 12.8% | 18.9% | 16.9% | 16.4% | 17.4% | 28.1% | 31.5% |
| Debt to Equity | 0.15x | 0.09x | 0.09x | 0.16x | 0.16x | 0.08x | 0.00x | 0.04x | 0.13x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenyang Xingqi Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.88%
- Forward dividend
- 1.30 CNY
- Payout ratio
- 50.5%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 351M | 0.98 | 50.5% |
| 2024 | CNY 467M | 2.66 | 138.0% |
| 2023 | CNY 177M | 1.43 | 73.8% |
| 2022 | CNY 79.3M | 0.64 | 37.5% |
| 2021 | CNY 41.2M | 0.48 | 21.1% |
| 2020 | CNY 10.3M | 0.13 | 11.7% |
| 2019 | CNY 20.0M | 0.18 | 55.7% |
| 2018 | CNY 22.9M | 0.28 | 167.5% |
| 2017 | CNY 13.0M | 0.16 | 33.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.45:1 on May 22, 2026.
Who owns Shenyang Xingqi Pharmaceutical Co Ltd
- Insiders 32.77%
- Institutions 2.85%
- Public & others 64.38%
- Shares outstanding 355M
- Free float 243M
Shenyang Xingqi Pharmaceutical Co Ltd company profile
- Company name
- Shenyang Xingqi Pharmaceutical Co Ltd
- Ticker
- 300573.SHE
- ISIN
- CNE100002DV1
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,396
- Fiscal year end
- December
- Address
- Building B, Enterprise Plaza, Shenyang, China, 110016
- Phone
- 86 24 2250 3989
- Website
- sinqi.com
About Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ophthalmic drugs in the People's Republic of China. The company offers myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory and anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs, intraocular rinsing fluids, pupil dilatant and ciliary muscle paralyzers, anti-fatigue medicines, dry eye treatment medicines, mydriatics and cycloplegia drugs, miotics and anti-glaucoma drugs, and intraoperative intraocular irrigation fluids. It also engages in technology development, technical advice, eye hospital, and research and experimental development activities. Shenyang Xingqi Pharmaceutical Co.,Ltd. was founded in 1977 and is based in Shenyang, the People's Republic of China.
Shenyang Xingqi Pharmaceutical Co Ltd management
7- Ms. E. GaoMD, GM & Non-Independent Director · born 1974
- Mr. Shaoyao ZhangDeputy Chairman, Deputy GM & Secretary of the Board · born 1970
- Ms. Yanan ChengDeputy GM, Financial Director, CFO & Non-Independent Director · born 1974
- Mr. Chunhua LiDirector of the Administrative Management Department & Director · born 1977
- Mr. Qiang YangHead of R&D Center, Deputy GM & Director · born 1984
- Xie MinHead of the Accounting Department & Accounting Supervisor
- Ms. Fei JiHuman Resources Specialist & Employee Representative Supervisor · born 1993